NCT03897868View on ClinicalTrials.gov

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions
Hypertension
Interventions
DRUG

HCP1803

HCP1803

DRUG

Amlodipine

Amlodipine

DRUG

Losartan

Losartan

DRUG

Placebo

Placebo

Trial Locations (1)

10326

Donggguk University Ilsan Hospital, Goyang-si

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT03897868 - A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension | Biotech Hunter | Biotech Hunter